View Exam | PowerPak

1. Use of opioids leading to “clinically significant impairment or distress” refers to which of the following?

A. Opioid dependence B. Opioid misuse C. Opioid use disorder D. Opioid addiction E. Unsure

2. All the following are concerning factors that can be identified using prescription drug monitoring programs (PDMP), EXCEPT:

A. Filling prescriptions from multiple providers B. High daily dosage of opioids C. Concurrent use of benzodiazepines D. Concomitant use of alcohol E. Unsure

3. After accessing a patient's information on the PDMP, you notice that the patient is filling opioid prescriptions from multiple providers. What is an appropriate next step?

A. Refuse to fill the medication and dismiss the patient from your pharmacy B. Call the Drug Enforcement Agency and report that the patient is “doctor shopping” C. Discuss your concerns with the patient and counsel on the importance of obtaining controlled substance prescriptions from one provider D. Tell the patient that the medication is out of stock E. Unsure

4. Which of the following describes a program where pharmacists reach out and visit health care professionals to provide evidence-based education on optimal use of opioid medications to treat chronic pain?

A. Academic detailing B. Medication therapy management C. Opioid Risk Tool D. Opioid exit plans E. Unsure

5. All the following counseling points are appropriate reasons for naloxone administration, EXCEPT:

A. Inability to awaken B. Slow or shallow breathing C. Trembling hands D. Pinpoint pupils with slow breathing E. Unsure

6. All the following are appropriate counseling points on naloxone administration by a caregiver, EXCEPT:

A. The nasal spray can be reused if the patient requires multiple doses B. Call emergency medical assistance immediately after administering naloxone C. Administer the pre-filled auto-injector in the middle of the outer thigh D. If administering the nasal spray, first lay the patient on their back E. Unsure

7. Which of the following drugs used for MAT requires intensive monitoring and must be obtained from an opioid treatment program?

A. Methadone B. Buprenorphine C. Naltrexone D. Naloxone E. Unsure

8. All the following aspects of MAT are true, EXCEPT:

A. Patients can start naltrexone without first undergoing opioid withdrawal B. Methadone is an appropriate treatment in pregnant women with OUD C. Buprenorphine is also formulated in combination with naloxone D. Immediate-release naltrexone has low adherence rates E. Unsure

9. According to SAMHSA recommendations, treatment with MAT in patients with OUD should continue:

A. For at least 1 year of maintenance therapy B. Until patients no longer experience opioid withdrawal C. For at least 10 years of maintenance therapy D. Indefinitely, for as long as it provides benefit and patients wish to continue E. Unsure

10. All the following are potential options to treat pain in patients with OUD treated with MAT (who require additional pain management with opioids), EXCEPT:

A. In patients taking methadone, short-acting opioids may be added for further pain management B. In patients taking buprenorphine, buprenorphine can be stopped, and a high-potency opioid added C. In patients taking naltrexone, mild pain should first be treated with short-acting opioids D. In patients taking buprenorphine, the buprenorphine dose may be increased to treat pain E. Unsure

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Use of opioids leading to “clinically significant impairment or distress” refers to which of the following?

2. All the following are concerning factors that can be identified using prescription drug monitoring programs (PDMP), EXCEPT:

3. After accessing a patient's information on the PDMP, you notice that the patient is filling opioid prescriptions from multiple providers. What is an appropriate next step?

4. Which of the following describes a program where pharmacists reach out and visit health care professionals to provide evidence-based education on optimal use of opioid medications to treat chronic pain?

5. All the following counseling points are appropriate reasons for naloxone administration, EXCEPT:

6. All the following are appropriate counseling points on naloxone administration by a caregiver, EXCEPT:

7. Which of the following drugs used for MAT requires intensive monitoring and must be obtained from an opioid treatment program?

8. All the following aspects of MAT are true, EXCEPT:

9. According to SAMHSA recommendations, treatment with MAT in patients with OUD should continue:

10. All the following are potential options to treat pain in patients with OUD treated with MAT (who require additional pain management with opioids), EXCEPT:

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Use of opioids leading to “clinically significant impairment or distress” refers to which of the following?

2. All the following are concerning factors that can be identified using prescription drug monitoring programs (PDMP), EXCEPT:

3. After accessing a patient's information on the PDMP, you notice that the patient is filling opioid prescriptions from multiple providers. What is an appropriate next step?

4. Which of the following describes a program where pharmacists reach out and visit health care professionals to provide evidence-based education on optimal use of opioid medications to treat chronic pain?

5. All the following counseling points are appropriate reasons for naloxone administration, EXCEPT:

6. All the following are appropriate counseling points on naloxone administration by a caregiver, EXCEPT:

7. Which of the following drugs used for MAT requires intensive monitoring and must be obtained from an opioid treatment program?

8. All the following aspects of MAT are true, EXCEPT:

9. According to SAMHSA recommendations, treatment with MAT in patients with OUD should continue:

10. All the following are potential options to treat pain in patients with OUD treated with MAT (who require additional pain management with opioids), EXCEPT:

« Return to Activity

Customers who Purchased
this Activity also Purchased